Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.

Details

Serval ID
serval:BIB_67DB51B93F8A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.
Journal
American Journal of Translational Research
Author(s)
Ghanem I., Riveiro M.E., Paradis V., Faivre S., de Parga P.M., Raymond E.
ISSN
1943-8141 (Electronic)
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
6
Number
4
Pages
340-352
Language
english
Notes
Publication types: Journal Article ; Review Publication Status: epublish
Abstract
Chemokines, a group of small chemotactic cytokines, and their G-protein-coupled receptors were originally identified for their ability to mediate various pro- and anti-inflammatory responses. Beyond the influence of chemokines and their cognate receptors in several inflammatory diseases, several malignancies have been shown to be dependent of chemokines for progression, tumor growth, cellular migration and invasion, and angiogenesis; those later facilitating the development of distant metastases. In hepatocellular carcinoma (HCC), chemokines were shown to affect leukocyte recruitment, neovascularization and tumor progression. CXCL12 (stromal-derived factor 1 alpha- SDF-1) is the primary ligand for the seven transmembrane G-protein coupled receptor CXCR4. The CXCR4/CXCL12 axis exerts a variety of functions at different steps of HCC tumor progression, using autocrine and/or paracrine mechanisms to sustain tumor cell growth, to induce angiogenesis and to facilitate tumor escape through evasion of immune surveillance. In this review, we have comprehensively described the role of CXCR4/CXCL12 in HCC and also investigated the role of CXCR7, an alternative receptors that also binds CXCL12 with potentially distinct downstream effects. Preclinical data converge to demonstrate that inhibition of the CXCR4/CXCL12 axis may lead to direct inhibition of tumor migration, invasion, and metastases. This pathway is under investigation to identify potential novel treatments in HCC and other cancers. However, one of the major challenges faced in this emerging field targeting the CXCR4/CXCL12 signaling pathway, is the translation of current knowledge into the design and development of effective inhibitors of CXCR4 and/or CXCL12 for cancer therapy.
Pubmed
Create date
11/02/2015 12:05
Last modification date
20/08/2019 14:23
Usage data